AKT1 and neoplasm: As expected, there were significantly higher volumes of subcutaneous tumors in the MIF group compared to the other groups (Figure 6A), indicating that in vivo, MIF contributes to tumor progression and could be inhibited by blocking CXCR4-AKT pathway activity.